Novo Nordisk announced today that it entered into exclusive negotiations for a controlling stake in drug delivery device maker Biocorp.
France-based Biocorp specializes in the design, development and manufacturing of delivery systems and medical devices. Its offerings include Mallya, a Bluetooth-enabled smart add-on device for pen injectors.
Mallya, a smart sensor, attaches directly to insulin pen injectors to make them connected devices. It automatically collects and records key treatment information and transmits it to a dedicated digital application. That data includes selected insulin units, date and time of injection. The FDA cleared Mallya in December 2022.
Novo Nordisk and Biocorp have collaborated on Mallya’s development and commercialization since 2021. It pairs with the FlexTouch pen for people with diabetes. The two companies expanded their partnership to the development of Mallya versions for other therapy areas.
Get the full story at our sister site, Drug Delivery Business News.